These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18313860)

  • 21. Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability.
    Ehlers CL; Gizer IR; Vieten C; Gilder DA; Stouffer GM; Lau P; Wilhelmsen KC
    Addict Behav; 2010 Feb; 35(2):102-10. PubMed ID: 19818563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Withdrawal, Mood, and Sleep Inventories After Monitored 3-Week Abstinence in Cannabis-Using Adolescents and Young Adults.
    Sullivan RM; Wallace AL; Stinson EA; Montoto KV; Kaiver CM; Wade NE; Lisdahl KM
    Cannabis Cannabinoid Res; 2022 Oct; 7(5):690-699. PubMed ID: 34678051
    [No Abstract]   [Full Text] [Related]  

  • 23. Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients.
    Preuss UW; Watzke AB; Zimmermann J; Wong JW; Schmidt CO
    Drug Alcohol Depend; 2010 Jan; 106(2-3):133-41. PubMed ID: 19783382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
    Mason BJ; Crean R; Goodell V; Light JM; Quello S; Shadan F; Buffkins K; Kyle M; Adusumalli M; Begovic A; Rao S
    Neuropsychopharmacology; 2012 Jun; 37(7):1689-98. PubMed ID: 22373942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.
    Weinstein AM; Miller H; Bluvstein I; Rapoport E; Schreiber S; Bar-Hamburger R; Bloch M
    Am J Drug Alcohol Abuse; 2014 Jan; 40(1):16-22. PubMed ID: 24359507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness.
    Schuster RM; Fontaine M; Nip E; Zhang H; Hanly A; Evins AE
    Prev Med; 2017 Nov; 104():40-45. PubMed ID: 28242263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. State of the art treatments for cannabis dependence.
    Danovitch I; Gorelick DA
    Psychiatr Clin North Am; 2012 Jun; 35(2):309-26. PubMed ID: 22640758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment.
    Lee D; Schroeder JR; Karschner EL; Goodwin RS; Hirvonen J; Gorelick DA; Huestis MA
    Am J Addict; 2014; 23(3):234-42. PubMed ID: 24724880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents.
    Chung T; Martin CS; Cornelius JR; Clark DB
    Addiction; 2008 May; 103(5):787-99. PubMed ID: 18412757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
    Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
    CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabis withdrawal syndrome: An important diagnostic consideration in adolescents presenting with disordered eating.
    Chesney T; Matsos L; Couturier J; Johnson N
    Int J Eat Disord; 2014 Mar; 47(2):219-23. PubMed ID: 24281745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
    Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
    BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
    Levin FR; Mariani J; Brooks DJ; Pavlicova M; Nunes EV; Agosti V; Bisaga A; Sullivan MA; Carpenter KM
    Addiction; 2013 Jun; 108(6):1084-94. PubMed ID: 23297841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabis withdrawal among non-treatment-seeking adult cannabis users.
    Copersino ML; Boyd SJ; Tashkin DP; Huestis MA; Heishman SJ; Dermand JC; Simmons MS; Gorelick DA
    Am J Addict; 2006; 15(1):8-14. PubMed ID: 16449088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.
    D'Souza DC; Cortes-Briones J; Creatura G; Bluez G; Thurnauer H; Deaso E; Bielen K; Surti T; Radhakrishnan R; Gupta A; Gupta S; Cahill J; Sherif MA; Makriyannis A; Morgan PT; Ranganathan M; Skosnik PD
    Lancet Psychiatry; 2019 Jan; 6(1):35-45. PubMed ID: 30528676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The reliability of self-reported cannabis abuse, dependence and withdrawal symptoms: multisite study of differences between general population and treatment groups.
    Mennes CE; Ben Abdallah A; Cottler LB
    Addict Behav; 2009 Feb; 34(2):223-6. PubMed ID: 19004561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
    Cornelius JR; Clark DB; Bukstein OG; Birmaher B; Salloum IM; Brown SA
    Addict Behav; 2005 Oct; 30(9):1824-33. PubMed ID: 16102905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.
    Cornelius JR; Bukstein OG; Wood DS; Kirisci L; Douaihy A; Clark DB
    Addict Behav; 2009 Oct; 34(10):905-9. PubMed ID: 19321268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychiatric aspects of cannabis use in adolescents and young adults.
    Tunving K
    Pediatrician; 1987; 14(1-2):83-91. PubMed ID: 3497393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.